Journal of Oncology Pharmacy Practice · 2024 · 19 citations · 84 references
PharmacyPharmaceuticsPharmacologyCancer PharmacologyChemotherapyDrug DeliveryCancer Drug DeliveryDrug Delivery EngineeringNanocarriers For TherapeuticsNanoparticle FormulationsPharmacokinetics Of Anticancer DrugsPolymeric Drug Delivery SystemsChemotherapy DeliveryDrug Delivery NanocarriersDrug-loaded MicellesIntraperitoneal AdministrationLiposomesMicellesPolymeric MicellesSolubility
PURPOSE: Paclitaxel is an effective chemotherapeutic agent against a variety of cancer types. However, the clinical utility of paclitaxel is restricted by its poor solubility in water and high toxicity, resulting in low drug tolerance. These difficulties could be resolved by using suitable pharmacological carriers. Hence, it is essential to determine innovative methods of administering this effective medication to overcome paclitaxel's inherent limitations. METHODS: An extensive literature search was conducted using multiple electronic databases to identify relevant studies published. RESULTS: In this comprehensive analysis, many different paclitaxel delivery systems are covered and discussed, such as albumin-bound paclitaxel, polymeric micelles, paclitaxel-loaded liposomes, prodrugs, cyclodextrins, and peptide-taxane conjugates. Moreover, the review also covers various delivery routes of conventional paclitaxel or novel paclitaxel formulations, such as oral administration, local applications, and intraperitoneal delivery. CONCLUSION: In addition to albumin-bound paclitaxel, polymeric micelles appear to be the most promising formulations for innovative drug delivery systems at present. A variety of variants of polymeric micelles are currently undergoing advanced phases of clinical trials.
84
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena et al. · New England Journal of Medicine · 2013 · 6.7K citations
Medicine, Oncology, Pharmacology +13
William J. Gradishar, Sergei Tjulandin, Neville Davidson et al. · Journal of Clinical Oncology · 2005 · 2.1K citations · Full text
Pharmacy, Oncology, Pharmacology +15
Hypersensitivity reactions from taxol.
R B Weiss, Ross C. Donehower, Peter H. Wiernik et al. · Journal of Clinical Oncology · 1990 · 1.2K citations
Medicine, Oncology, Pharmacology +9